Co-treatment with ginsenoside Rh2 and betulinic acid synergistically induces apoptosis in human cancer cells in association with enhanced capsase-8 activation, bax translocation, and cytochrome c release

Molecular Carcinogenesis

Volumn 50, Issue 10, 2011, Pages 760-769

  Li, Qing ^a,b,c   Li, Yang ^a,b   Wang, Xiaoyu ^a   Fang, Xuexun ^a   He, Kan ^a   Guo, Xiaoxi ^a   Zhan, Zhuo ^a   Sun, Chao ^a   Jin, Ying Hua ^a,b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b Jilin University   (China)

^c DALIAN UNIVERSITY   (China)

Author keywords

Apoptosis; Bax translocation; Betulinic acid; Cytochrome c release; Ginsenoside Rh2; Synergistic effect

Indexed keywords

BETULIC ACID; CASPASE 8; CASPASE 9; CYTOCHROME C; GINSENOSIDE RH 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME RELEASE; HELA CELL; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN TRANSPORT;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BLOTTING, WESTERN; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; FLOW CYTOMETRY; GINSENOSIDES; HELA CELLS; HEP G2 CELLS; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN TRANSPORT; RNA INTERFERENCE; TRITERPENES;

EID: 80052296792     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20673     Document Type: Article

References (34)

1. Martin BJ, Laura DA. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005; 5: 231-237.
2. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98: 2603-2614.
3. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-495.
4. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164.
5. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
6. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430.
7. Van LG, Saelens X, Van GM, MacFarlane M, Martin SJ, Vandenabeele P. The role of mitochondrial factors in apoptosis: A Russian roulette with more than one bullet. Cell Death Differ 2002; 9: 1031-1042.
8. Simone F, Klaus-Michael D. Sensitization for anticancer drug-induced apoptosis by betulinic acid. Neoplasia 2005; 7: 162-170.
9. Tatsuka M, Maeda M, Ota T. Anticarcinogenic effect and enhancement of metastatic potential of BALB/c 3T3 cell by ginsenoside Rh2. Jpn J Cancer Res 2001; 92: 1184-1189.
10. Nakata H, Kikuchi Y, Tode T, Hirata J, Kita T. Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells. Jpn J Cancer Res 1998; 89: 733-740.
11. Oh M, Choi YH, Choi S, et al. Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. Int J Oncol 1999; 14: 869-875.
12. Jin YH, Yoo KJ, Lee YH, Lee SK. Caspase 3-mediated cleavage of p21WAF1/CIP1 associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells. J Biol Chem 2000; 275: 30256-30263.
13. Popovich DG, Kitts DD. Structure-function relationship exists for ginsenosides in reducing cell proliferation and induce apoptosis in the human leukemia (THP-1) cell line. Arch Biochem Biophys 2002; 406: 1-8.
14. Chi-Chih C, Shu-Mei Y, Chi-Ying H, Jung-Chou C, Wei-Mao C, Shih-Lan H. Molecular mechanisms of ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells. Cancer Chemother Pharmacol 2005; 55: 531-540.
15. Kim HE, Oh JH, Lee SK, Oh YJ. Ginsenoside RH-2 induces apoptotic cell death in rat C6 glioma via a reactive oxygen- and caspase-dependent but Bcl-x(L)-independent pathway. Life Sci 1999; 65: PL33-PL40.
16. Park JA, Lee KY, Oh YJ, Kim KW, Lee SK. Activation of caspase-3 protease via a Bcl-2-insensitive pathway during the process of ginsenoside Rh2-induced apoptosis. Cancer Lett 1997; 121: 73-81.
17. Kim YS, Jin SH, Lee YH, Kim SI, Park JD. Ginsenoside Rh2 induces apoptosis independently of Bcl-2, Bcl-xL, or Bax in C6Bu-1 cells. Arch Pharm Res 1999; 22: 448-453.
18. Pisha E, Chai H, Lee IS, et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1995; 1: 1046-1051.
19. Fulda S, Jeremias I, Pietsch T, Debatin KM. Betulinic acid: A new chemotherapeutic agent in the treatment of neuroectodermal tumors. Klin Padiatr 1999; 211: 319-322.
20. Zuco V, Supino R, Righetti SC, et al. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 2002; 175: 17-25.
21. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
22. Fulda S, Friesen C, Los M, et al. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 1997; 57: 4956-4964.
23. Li R, Boehm AL, Miranda MB, Shangary S, Grandis JR, Johnson DE. Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells. Neoplasia 2007; 9: 801-811.
24. EL-Deiry WS. Meeting report: The international conference on tumor progression and therapeutic resistance. Cancer Res 2005; 65: 4475-4484.
25. Simone F, Irmela J, Klaus-Michael D. Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. Oncogene 2004; 23: 7611-7620.
26. Maria N, Alessandra C, Irina M, Alberto MM. Synergistic induction of apoptosis in human leukemia T cell by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer ther 2006; 5: 1559-1570.
27. Spänkuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene 2007; 26: 5793-5807.
28. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNF-alpha-mediated cell death. Science 2004; 305: 1411-1413.
29. Fulda S, Jeremias I, Steiner HH, Pietsch T, Debatin KV. Betulinic acid: A new cytotoxic agent against malignant brain-tumor cells. Int J Cancer 1999; 82: 435-441.
30. Tan Y, Yu R, Pezzuto JM. Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen activated protein kinase activation. Clin Cancer Res 2003; 9: 2866-2875.
31. Selzer E, Pimentel E, Wacheck V, et al. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J Invest Dermatol 2000; 114: 935-940.
32. Fulda S, Scaffidi C, Susin SA, et al. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem 1998; 273: 33942-33948.
33. Eskes R, Desagher S, Antonsson B, Martinou JC. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 2000; 20: 929-935.
34. Jana W, Clarissa VH, Philipp H, Claus B, Bernd D, Peter TD. TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene 2005; 24: 4052-4064.